Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Canopy Growth CorporationNASDAQ: CGC

Operating Income · Q4 FY2025 · quarter ended Mar 2026

Operating income remains negative

Q4 FY2025 operating income was -CA$27.47M, compared with -CA$18.27M a year earlier. Trailing-twelve-month operating income was -CA$103.15M.

Context

  • Operating income amounted to 33.4% of revenue in FY2025, down 10.1 pp from a year earlier.
  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 5 analysts of CA$25.59M (+115.8%) for the fiscal year ending Mar 2027, a step up from the -38.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$27.47M+24.0% QoQ
Last fiscal yearMar 2026
-CA$161.66M-38.0% YoY
LTMMar 2026
-CA$103.15M+11.9% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.4%+78.4%+128.7 pp
1 year-38.0%+115.8%+153.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

CAD · from the income statement

Latest · FY2025
(161.66M) CAD
Year-over-year change
-38.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.9% is the 6th highest of 9, against a peer median of +36.2%.
  • Operating income amounts to 33.0% of revenue for CGC, versus a peer median of 61.4%.
CGC Competitors
Operating Income for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$201.84M USD+280.9%-22.0%55.8%
DHDefinitive Healthcare Corp.LTM Mar 2026$159.37M USD+118.1%—66.9%
ACBAurora Cannabis Inc.LTM Mar 2026CA$789.11K CAD-84.1%—0.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$78K USD——0.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$16.31M USD+29.5%—39.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$80.48M USD+43.0%—961.9%
BIOABioAge Labs, Inc.LTM Mar 2026-$101.71M USD-24.3%—985.9%
CGCCanopy Growth CorporationLTM Mar 2026-CA$103.15M CAD+11.9%—33.0%
CABACabaletta Bio, Inc.LTM Mar 2026-$179.4M USD-33.6%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$191.86M USD+46.8%—618909.7%
Peer median (excluding CGC) —+36.2%-22.0%61.4%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.